Clinical Development Failure Risk: Their pipeline candidates (e.g., opaganib, RHB-107) might fail to demonstrate efficacy or safety in clinical trials, or trials may be delayed, leading to significant setbacks and loss of investment.

Regulatory Approval Uncertainty Risk: Even with positive trial results, obtaining regulatory approvals from bodies like the FDA or EMA is not guaranteed and can be a lengthy, unpredictable process, potentially preventing products from reaching the market.

Commercialization and Market Adoption Challenges Risk: Their approved products (Talicia, Movantik, Aemcolo) may not achieve expected sales due to various factors such as physician adoption, payer coverage, competition, or market awareness, impacting revenue generation.